- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05564403
Studie av kemoterapi, med eller utan binimetinib vid avancerad gallvägscancer i 2nd Line Setting (A ComboMATCH Treatment Trial)
En ComboMATCH-behandlingsprövning: FOLFOX i kombination med Binimetinib som 2nd-line terapi för patienter med avancerad gallvägscancer med förändringar i MAPK-vägen
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other places in the body (advanced) and had progression of cancer after previous treatments (2nd line setting). Fluorouracil is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It works by killing tumor cells. Leucovorin may help the other drugs in the mFOLFOX6 chemotherapy regimen work better by making tumor cells more sensitive to the drugs. Binimetinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps to stop or slow the spread of tumor cells. Giving binimetinib in combination with mFOLFOX6 chemotherapy may be effective in shrinking or stabilizing advanced biliary tract cancers in the 2nd line setting.
Studieöversikt
Status
Betingelser
- Steg III intrahepatisk kolangiokarcinom AJCC v8
- Steg III Gallblåscancer AJCC v8
- Återkommande gallblåsakarcinom
- Inoperabel gallblåsecancer
- Steg III Hilar Cholangiocarcinoma AJCC v8
- Steg IV Gallblåscancer AJCC v8
- Steg IV Hilar Cholangiocarcinoma AJCC v8
- Steg IV intrahepatisk kolangiokarcinom AJCC v8
- Steg IV Distal gallgångscancer AJCC v8
- Inoperabelt intrahepatiskt kolangiokarcinom
- Avancerat gallvägskarcinom
- Avancerat intrahepatiskt kolangiokarcinom
- Återkommande intrahepatisk kolangiokarcinom
- Steg III Distal gallgångscancer AJCC v8
- Avancerat gallblåsecancer
- Återkommande gallvägskarcinom
- Ooperabelt gallvägskarcinom
Intervention / Behandling
- Läkemedel: Fluorouracil
- Procedur: Computed Tomography
- Procedur: Magnetic Resonance Imaging
- Procedur: Echocardiography Test
- Procedur: Multigated Acquisition Scan
- Procedur: Biopsy Procedure
- Procedur: Biospecimen Collection
- Läkemedel: Binimetinib
- Läkemedel: Leucovorin Calcium
- Läkemedel: Oxaliplatin
- Procedur: Bone Scan
Detaljerad beskrivning
PRIMARY OBJECTIVE:
I. To determine whether binimetinib and mFOLFOX6 combination therapy improves overall survival (OS) compared to mFOLFOX6 alone in patients with advanced/recurrent biliary tract cancer (BTC) and with alterations in RAS/RAF/MEK/ERK pathway, who have progressed on one prior line of therapy.
SECONDARY OBJECTIVES:
I. To determine whether binimetinib and mFOLFOX6 combination therapy improves objective response rate (ORR) compared to FOLFOX alone.
II. To determine if clinical outcomes including progression free survival (PFS), duration of response (DOR), and disease control rate (DCR) are improved with combination treatment of binimetinib and mFOLFOX6 compared to FOLFOX alone in patients with advanced/recurrent BTC and with alterations in RAS/RAF/MEK/ERK pathway who have progression on one prior line of therapy.
III. Toxicity and tolerability will be evaluated within and between the two treatment arms, where frequency, type, and severity of adverse events will be assessed per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v)5.0.
IV. Collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor deoxyribonucleic acid (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.
EXPLORATORY OBJECTIVES:
I. Generate a prognostic model of MAPK mutations for this patient population using clinical, laboratory and molecular features of their disease and clinical outcome to validate on future samples.
II. Correlation of outcome with albumin. III. Assess the correlation between the presence of MAPK pathway mutations and activity of addition of binimetinib therapy to standard 2nd line chemotherapy.
IV. Conduct whole-exome sequencing and ribonucleic acid (RNA)-sequencing at baseline, and on optional biopsy upon progression to assess determinants of response and resistance.
V. Explore changes in plasma MAPK mutations allelic burden and other molecular findings at baseline and upon progression using ctDNA and correlate changes with clinical activity, disease course as well as response/resistance to therapy.
VI. Evaluate if our machine learning algorithm for RAS/RAF/MEK/ERK pathway mutations correlates with detection of mutations as well as prediction of outcomes from samples obtained in this study.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive leucovorin intravenously (IV) over 2 hours and oxaliplatin IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood during screening and on study, and undergo computed tomography (CT) with contrast, magnetic resonance imaging (MRI), or fludeoxyglucose F-18 positron emission tomography (FDG-PET) throughout the trial as clinically indicated. Patients may also undergo bone scans on study and may undergo biopsies throughout the study as clinically indicated.
ARM 2: Patients receive binimetinib orally (PO) on days 1-14, and leucovorin IV, oxaliplatin IV, and fluorouracil IV as in Arm 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiogram (ECHO) or multigated acquisition scan (MUGA) and collection of blood during screening and on study, and undergo CT with contrast, MRI, or FDG-PET throughout the trial as clinically indicated. Patients may also undergo bone scans on study and may undergo biopsies throughout the study as clinically indicated.
After completion of study treatment, patients are followed up every 8 weeks until disease progression, thereafter patients are followed for survival every 4 months for up to 5 years following registration.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Förenta staterna, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85054
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Jonesboro, Arkansas, Förenta staterna, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
-
California
-
La Jolla, California, Förenta staterna, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, Förenta staterna, 90048
- Cedars-Sinai Medical Center
-
Whittier, California, Förenta staterna, 90602
- Presbyterian Intercommunity Hospital
-
-
Florida
-
Aventura, Florida, Förenta staterna, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Förenta staterna, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Förenta staterna, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Gainesville, Florida, Förenta staterna, 32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville, Florida, Förenta staterna, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Förenta staterna, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Förenta staterna, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Förenta staterna, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Hawaii
-
Honolulu, Hawaii, Förenta staterna, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Förenta staterna, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Förenta staterna, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Förenta staterna, 96817
- Queen's Cancer Center - Kuakini
-
‘Aiea, Hawaii, Förenta staterna, 96701
- Hawaii Cancer Care - Westridge
-
‘Ewa Beach, Hawaii, Förenta staterna, 96706
- The Queen's Medical Center - West Oahu
-
-
Idaho
-
Boise, Idaho, Förenta staterna, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Förenta staterna, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Förenta staterna, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Förenta staterna, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Förenta staterna, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Förenta staterna, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Förenta staterna, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Förenta staterna, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Förenta staterna, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Förenta staterna, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Barrington, Illinois, Förenta staterna, 60010
- Advocate Good Shepherd Hospital
-
Chicago, Illinois, Förenta staterna, 60611
- Northwestern University
-
Chicago, Illinois, Förenta staterna, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Förenta staterna, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Förenta staterna, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Förenta staterna, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Förenta staterna, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Förenta staterna, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Förenta staterna, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Förenta staterna, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, Förenta staterna, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Förenta staterna, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Förenta staterna, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Förenta staterna, 60123
- Advocate Sherman Hospital
-
Geneva, Illinois, Förenta staterna, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Förenta staterna, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Förenta staterna, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Hazel Crest, Illinois, Förenta staterna, 60429
- Advocate South Suburban Hospital
-
Lake Forest, Illinois, Förenta staterna, 60045
- Northwestern Medicine Lake Forest Hospital
-
Libertyville, Illinois, Förenta staterna, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Förenta staterna, 60048
- AMG Libertyville - Oncology
-
Mattoon, Illinois, Förenta staterna, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Förenta staterna, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Förenta staterna, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Förenta staterna, 60453-2699
- Advocate Christ Medical Center
-
Orland Park, Illinois, Förenta staterna, 60462
- University of Chicago Medicine-Orland Park
-
Orland Park, Illinois, Förenta staterna, 60462
- Northwestern Medicine Orland Park
-
Park Ridge, Illinois, Förenta staterna, 60068
- Advocate Lutheran General Hospital
-
Shiloh, Illinois, Förenta staterna, 62269
- Memorial Hospital East
-
Springfield, Illinois, Förenta staterna, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Förenta staterna, 62702
- Springfield Clinic
-
Springfield, Illinois, Förenta staterna, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Förenta staterna, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Förenta staterna, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Iowa
-
Ankeny, Iowa, Förenta staterna, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Des Moines, Iowa, Förenta staterna, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Waukee, Iowa, Förenta staterna, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maine
-
Brewer, Maine, Förenta staterna, 04412
- Lafayette Family Cancer Center-EMMC
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Förenta staterna, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Förenta staterna, 20889-5600
- Walter Reed National Military Medical Center
-
Cumberland, Maryland, Förenta staterna, 21502
- UPMC Western Maryland
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Förenta staterna, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Förenta staterna, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Förenta staterna, 48116
- University of Michigan - Brighton Center for Specialty Care
-
Brighton, Michigan, Förenta staterna, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Förenta staterna, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Förenta staterna, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Förenta staterna, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Förenta staterna, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Förenta staterna, 48124
- Corewell Health Dearborn Hospital
-
Farmington Hills, Michigan, Förenta staterna, 48336
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, Förenta staterna, 48503
- Hurley Medical Center
-
Flint, Michigan, Förenta staterna, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Förenta staterna, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Förenta staterna, 48503
- Cancer Hematology Centers - Flint
-
Lansing, Michigan, Förenta staterna, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Förenta staterna, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Macomb, Michigan, Förenta staterna, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Pontiac, Michigan, Förenta staterna, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Royal Oak, Michigan, Förenta staterna, 48073
- Corewell Health William Beaumont University Hospital
-
Troy, Michigan, Förenta staterna, 48085
- Corewell Health Beaumont Troy Hospital
-
Ypsilanti, Michigan, Förenta staterna, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Förenta staterna, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Bemidji, Minnesota, Förenta staterna, 56601
- Sanford Joe Lueken Cancer Center
-
Coon Rapids, Minnesota, Förenta staterna, 55433
- Mercy Hospital
-
Deer River, Minnesota, Förenta staterna, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Förenta staterna, 55805
- Essentia Health Cancer Center
-
Edina, Minnesota, Förenta staterna, 55435
- Fairview Southdale Hospital
-
Hibbing, Minnesota, Förenta staterna, 55746
- Essentia Health Hibbing Clinic
-
Maplewood, Minnesota, Förenta staterna, 55109
- Saint John's Hospital - Healtheast
-
Minneapolis, Minnesota, Förenta staterna, 55407
- Abbott-Northwestern Hospital
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Förenta staterna, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Förenta staterna, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Förenta staterna, 55102
- United Hospital
-
Sandstone, Minnesota, Förenta staterna, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Förenta staterna, 55792
- Essentia Health Virginia Clinic
-
-
Mississippi
-
Columbus, Mississippi, Förenta staterna, 39705
- Baptist Memorial Hospital and Cancer Center-Golden Triangle
-
Grenada, Mississippi, Förenta staterna, 38901
- Baptist Cancer Center-Grenada
-
New Albany, Mississippi, Förenta staterna, 38652
- Baptist Memorial Hospital and Cancer Center-Union County
-
Oxford, Mississippi, Förenta staterna, 38655
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Southhaven, Mississippi, Förenta staterna, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Cape Girardeau, Missouri, Förenta staterna, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Förenta staterna, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Förenta staterna, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Förenta staterna, 63640
- Parkland Health Center - Farmington
-
Sainte Genevieve, Missouri, Förenta staterna, 63670
- Sainte Genevieve County Memorial Hospital
-
St Louis, Missouri, Förenta staterna, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Förenta staterna, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Förenta staterna, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Förenta staterna, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, Förenta staterna, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Förenta staterna, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Förenta staterna, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Förenta staterna, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Förenta staterna, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Förenta staterna, 59901
- Logan Health Medical Center
-
Missoula, Montana, Förenta staterna, 59804
- Community Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Förenta staterna, 68123
- Nebraska Medicine-Bellevue
-
Omaha, Nebraska, Förenta staterna, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Förenta staterna, 68118
- Nebraska Medicine-Village Pointe
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Förenta staterna, 89183
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Förenta staterna, 89502
- Renown Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Buffalo, New York, Förenta staterna, 14263
- Roswell Park Cancer Institute
-
-
North Dakota
-
Bismarck, North Dakota, Förenta staterna, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Förenta staterna, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Förenta staterna, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Centerville, Ohio, Förenta staterna, 45459
- Miami Valley Hospital South
-
Dayton, Ohio, Förenta staterna, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Förenta staterna, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Förenta staterna, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Förenta staterna, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Förenta staterna, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Förenta staterna, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Förenta staterna, 45429
- Kettering Medical Center
-
Troy, Ohio, Förenta staterna, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Förenta staterna, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
-
Pennsylvania
-
Allentown, Pennsylvania, Förenta staterna, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Altoona, Pennsylvania, Förenta staterna, 16601
- UPMC Altoona
-
Bethlehem, Pennsylvania, Förenta staterna, 18017
- Lehigh Valley Hospital - Muhlenberg
-
East Stroudsburg, Pennsylvania, Förenta staterna, 18301
- Pocono Medical Center
-
Erie, Pennsylvania, Förenta staterna, 16505
- UPMC Hillman Cancer Center Erie
-
Greensburg, Pennsylvania, Förenta staterna, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Hazleton, Pennsylvania, Förenta staterna, 18201
- Lehigh Valley Hospital-Hazleton
-
Mechanicsburg, Pennsylvania, Förenta staterna, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, Förenta staterna, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Förenta staterna, 15237
- UPMC-Passavant Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Förenta staterna, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Förenta staterna, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, Förenta staterna, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Förenta staterna, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Conroe, Texas, Förenta staterna, 77384
- UT MD Anderson - The Woodlands
-
Houston, Texas, Förenta staterna, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Förenta staterna, 77079
- UT MD Anderson - West Houston
-
League City, Texas, Förenta staterna, 77573
- UT MD Anderson - League City
-
Sugar Land, Texas, Förenta staterna, 77478
- UT MD Anderson - Sugar Land
-
-
Virginia
-
Charlottesville, Virginia, Förenta staterna, 22908
- University of Virginia Cancer Center
-
Fairfax, Virginia, Förenta staterna, 22031
- Inova Schar Cancer Institute
-
Falls Church, Virginia, Förenta staterna, 22042
- Inova Fairfax Hospital
-
Richmond, Virginia, Förenta staterna, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Förenta staterna, 23229
- Virginia Cancer Institute
-
Richmond, Virginia, Förenta staterna, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Förenta staterna, 23970
- VCU Community Memorial Health Center
-
-
Washington
-
Edmonds, Washington, Förenta staterna, 98026
- Swedish Cancer Institute-Edmonds
-
Issaquah, Washington, Förenta staterna, 98029
- Swedish Cancer Institute-Issaquah
-
Renton, Washington, Förenta staterna, 98055
- Valley Medical Center
-
Seattle, Washington, Förenta staterna, 98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Morgantown, West Virginia, Förenta staterna, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Appleton, Wisconsin, Förenta staterna, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Förenta staterna, 54806
- Duluth Clinic Ashland
-
Berlin, Wisconsin, Förenta staterna, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Förenta staterna, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy, Wisconsin, Förenta staterna, 53110
- Aurora Saint Luke's South Shore
-
Germantown, Wisconsin, Förenta staterna, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Förenta staterna, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Förenta staterna, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, Förenta staterna, 53142
- Aurora Cancer Care-Kenosha South
-
Marinette, Wisconsin, Förenta staterna, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Förenta staterna, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Förenta staterna, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Förenta staterna, 53233
- Aurora Sinai Medical Center
-
Neenah, Wisconsin, Förenta staterna, 54956
- ThedaCare Regional Medical Center - Neenah
-
Oshkosh, Wisconsin, Förenta staterna, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Förenta staterna, 53406
- Aurora Cancer Care-Racine
-
Sheboygan, Wisconsin, Förenta staterna, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Förenta staterna, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Förenta staterna, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wauwatosa, Wisconsin, Förenta staterna, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Förenta staterna, 53227
- Aurora West Allis Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-A6 based on the presence of an actionable mutation as defined in EAY191
-
GENERAL COMBOMATCH EAY191:
-
Patients must be registered to the ComboMATCH Registration Protocol (EAY191)
-
Patients must have RAS/RAF/MEK/ERK mutations as determined by the ComboMATCH screening assessment
-
Patients must not have BRAF V600E as determined by the ComboMATCH screening assessment
-
Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have archival tissue available from within 12 months prior to registration on the ComboMATCH Registration Trial (EAY191).
-
Please note the current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website
-
Please note novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH Registration Protocol
-
EAY191-A6 REGISTRATION:
-
Participants must have histologically confirmed BTC (intrahepatic cholangiocarcinoma [IHC], extrahepatic cholangiocarcinoma [EHC] or gallbladder cancer [GBC]) that is unresectable or recurrent with a confirmed RAS/RAF/MEK/ERK pathway mutation via any Clinical Laboratory Improvement Act (CLIA)-certified method. BRAFV600E mutations are not eligible due to other ongoing/upcoming studies in this disease cohort
-
Tumor tissue must be available:
-
Adequate archival tumor specimen (obtained within 12 months of EAY191 registration which has not had a Response Evaluation Criteria in Solid Tumors (RECIST) response, complete response (CR) or partial response (PR), to any intervening therapy after collection of the tissue) must be available with formalin-fixed paraffin-embedded tumor tissue (blocks or slides) OR
-
Consent to a new tumor tissue biopsy which is not a representative target lesion. This lesion must be amenable to a minimal risk image-guided or direct vision biopsy
- A new biopsy is preferred but is not required for enrollment in EAY191-A6 if sufficient archival tissue is available as described above.
-
-
Measurable disease per RECIST 1.1 Of note, in the case when a baseline biopsy is done after scans are obtained, a lesion separate from one that is biopsied needs to be measurable per RECIST 1.1. All radiologic studies must be performed within 28 days prior to registration
-
Progression of disease on gemcitabine based first-line regimen (i.e. only one prior line of therapy is permitted)
-
No systemic anti-cancer therapy within 4 weeks of registration to EAY191-A6
-
No prior MEK inhibitor therapy
-
No prior history of treatment with a direct and specific inhibitor of KRAS
-
Patients who only received radio-sensitizing chemotherapy with fluorouracil (5-FU) or capecitabine are eligible, but need to have received and failed first-line systemic chemotherapy upon recurrence. Peri-operative systemic 5-FU/capecitabine and/or oxaliplatin, is allowed if it's been more than 12 months of registration to EAY191-A6
-
No major surgery within 4 weeks (excluding placement of vascular access) of registration to EAY191-A6
-
No minor surgery within 2 weeks of registration to EAY191-A6
-
No palliative radiotherapy within 1 week of registration to EAY191-A6
-
Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown
- Therefore, for women of childbearing potential only, a negative pregnancy test done =< 14 days prior to registration is required
- Adequate contraception is needed for at least 30 days after the last dose of binimetinib and breastfeeding should be discontinued for at least 3 days after the last dose of binimetinib. For FOLFOX regimen, 9 months is recommended for contraception after last dose of oxaliplatin for females of childbearing potential and 6 months for males
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Absolute neutrophil count (ANC) >= 1,000/mm^3, no growth factor within 14 days of 1st dose
-
Platelet count >= 75,000/mm^3
-
Creatinine < 1.6 x upper limit of normal (ULN) OR
-
Calculated (Calc.) creatinine clearance >= 50 mL/min, as calculated by the Cockcroft-Gault formula
-
Total bilirubin =< 2.0 x upper limit of normal (ULN); Patients with Gilbert syndrome may enroll if < 3.0 x ULN
-
Aspartate aminotransferase (AST) /alanine aminotransferase (ALT) =< 5.0 x upper limit of normal (ULN)
-
Hemoglobin >= 8 g/dL, no transfusion within 7 days of 1st dose
-
Creatine phosphokinase =< 2.5 x ULN
-
High blood pressure more than 160/90 despite treatment are ineligible
-
No history of interstitial lung disease. No history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
-
Patients should not have history of bowel perforation or intestinal fistulas in the last 6 months
-
Patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease are ineligible
-
Must have adequate cardiac function with left ventricular ejection fraction >= 50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan. Patients with congenital long QT syndrome are not permitted
-
No history of prolonged QTc or at risk for prolonged QTc due to any reason (for example, concomitant medications during or before chemotherapy that may increase the risk of prolonged QTc), uncontrolled congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]), myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina or severe obstructive pulmonary disease
-
No active skin disorder that has required systemic therapy within the past 1 year
-
No history of rhabdomyolysis
-
No concurrent ocular disorders, including:
- Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including but not limited to uncontrolled hypertension, uncontrolled diabetes
- Patients with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure > 21 mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO
- Patients with a history of corneal erosion (instability of corneal epithelium), corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions
- Patients with known or at risk for retinopathies, uveitis or retinal vein occlusion
-
No patients with a history of hypersensitivity to any of the inactive ingredients in binimetinib, nor known severe allergic reactions or hypersensitivity of 5-FU, leucovorin (LV) or oxaliplatin will be allowed to participate in this study for safety concerns
-
No other medical condition (e.g. cardiac, gastrointestinal, pulmonary, psychiatric, neurological, genetic, etc.) that in the opinion of the investigator would places the subject at unacceptably high risk for toxicity
-
No prior allogeneic stem cell or solid organ transplantation
-
Central nervous system (CNS) metastases must have been treated with local therapy (surgery, radiation, ablation) with systemic steroids tapered to a physiologic dose (10 mg or prednisone equivalent or less)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients must not have grade 2 neuropathy or greater, within 14 days prior to registration
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm 1 (mFOLFOX6)
Patients receive leucovorin IV over 2 hours and oxaliplatin IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood during screening and on study, and undergo CT with contrast, MRI, or FDG-PET throughout the trial as clinically indicated. Patients may also undergo bone scans on study and may undergo biopsies throughout the study as clinically indicated. |
Given IV
Andra namn:
Undergo CT
Andra namn:
Undergo MRI
Andra namn:
Undergo biopsy
Andra namn:
Undergo collection of blood
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo bone scan
Andra namn:
|
|
Experimentell: Arm 2 (binimetinib, mFOLFOX6)
Patients receive binimetinib PO on days 1-14, and leucovorin IV, oxaliplatin IV, and fluorouracil IV as in Arm 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA and collection of blood during screening and on study, and undergo CT with contrast, MRI, or FDG-PET throughout the trial as clinically indicated. Patients may also undergo bone scans on study and may undergo biopsies throughout the study as clinically indicated. |
Given IV
Andra namn:
Undergo CT
Andra namn:
Undergo MRI
Andra namn:
Undergo ECHO
Andra namn:
Undergo MUGA
Andra namn:
Undergo biopsy
Andra namn:
Undergo collection of blood
Andra namn:
Given PO
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo bone scan
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall survival (OS)
Tidsram: From randomization to the time of death due to any cause, assessed up to 30 months
|
The primary efficacy analysis will be to compare the OS distributions between those treated with modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) and binimetinib versus (vs.) mFOLFOX6. Despite being a randomized phase II trial, we will utilize an intent to treat approach such that patients will be analyzed based on the treatment arm to which they were randomized. As defined above, OS will be compared between the two treatment arms using Kaplan-Meier methods. The hazard ratio, median OS, and estimated OS rates at 6, 12, 18, 24, and 30 months will be estimated along with corresponding 95% confidence intervals. Anticipating that the treatment arms will be balanced in terms of the potential confounders reflect in the stratification factors, a log-rank test will be used to compare the OS distributions between the two treatment arms in this cohort. |
From randomization to the time of death due to any cause, assessed up to 30 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective response
Tidsram: Up to 5 years
|
Objective response by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria will be estimated using objective response rate (ORR) where ORR is defined as the number of evaluable patients achieving a response (partial response [PR] or complete response [CR] per RECIST v1.1) during treatment with study therapy divided by the total number of evaluable patients. Rates of response will be compared across arms using a Chi-Square Test for Proportion. Point estimates will be generated for objective response rates within each arm along with 95% confidence intervals using the Clopper-Pearson method. |
Up to 5 years
|
|
Progression free survival (PFS)
Tidsram: From study entry to the first of either disease progression or death from any cause, assessed up to 5 years
|
Disease progression will be determined based on RECIST 1.1 criteria. PFS will be estimated using the Kaplan-Meier method. The median PFS and 95% confidence interval will be reported. Patients will be censored at the last disease assessment date. |
From study entry to the first of either disease progression or death from any cause, assessed up to 5 years
|
|
Duration of response (DoR)
Tidsram: Up to 5 years
|
Defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented, or death if no prior evidence of disease progression. The distribution of DoR will be estimated using the method of Kaplan-Meier. |
Up to 5 years
|
|
Clinical benefit
Tidsram: Up to 5 years
|
Defined as achieving CR, PR, or stable disease (SD) for at least 4 months while on treatment. Disease status will be assessed using RECIST v. 1.1 criteria. Clinical benefit rate (CBR) will be calculated as the proportion of evaluable patients who achieve clinical benefit. The final CBR point estimate and corresponding 95% confidence interval calculated using Clopper-Pearson method. |
Up to 5 years
|
|
Incidence of adverse events
Tidsram: Up to 5 years
|
Patients will be evaluated for adverse events using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events version 5.0. Summary statistics (e.g., mean, median, standard deviation) and frequency tables will be used to describe the distributions of adverse events. Rates of adverse events occurring in the treatment arm will be compared to the control arm with chi-squared tests (or suitable alternative) used for comparisons where applicable. Tolerability will also be evaluated, summarizing rates of dose delays or modifications, reasons patients end treatment, and time to end of active treatment. |
Up to 5 years
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Prognostic model/scoring system
Tidsram: Up to 5 years
|
Defined as presence of peritoneal disease/locally advanced disease/metastatic disease, Eastern Cooperative Oncology Group (ECOG) performance status, CA19.9 level. Will fit multivariate Cox regression models including MAPK mutation status, presence of peritoneal disease/locally advance disease/metastatic disease, ECOG performance status, and CA19-9 level, stratified by treatment arm. We will calculate C-statistics with 5-fold cross-validation |
Up to 5 years
|
|
Albumin
Tidsram: Up to 5 years
|
Will correlate outcome with albumin. |
Up to 5 years
|
|
Presence of MAPK pathway mutations
Tidsram: Up to 5 years
|
Will correlate with activity of addition of binimetinib therapy to standard 2nd line chemotherapy. |
Up to 5 years
|
|
Activity of addition of binimetinib therapy to standard 2nd line chemotherapy
Tidsram: Up to 5 years
|
Will correlate with presence of MAPK pathway mutations. |
Up to 5 years
|
|
Whole-exome sequencing and ribonucleic acid (RNA)-sequencing
Tidsram: Up to 5 years
|
Will be used to assess determinants of response and resistance. Concordance of diagnostic tumor mutation profile generated by the Designated Laboratory, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor deoxyribonucleic acid (ctDNA) mutation profile will be assessed. Details are provided in the statistical plan of the ComboMATCH Registration Protocol. |
Up to 5 years
|
|
Changes in plasma MAPK mutations allelic burden and other molecular findings
Tidsram: Up to 5 years
|
Will correlate changes with clinical activity, disease course as well as response/resistance to therapy. |
Up to 5 years
|
|
Detection of mutations as well as prediction of outcomes
Tidsram: Up to 5 years
|
Will evaluate if our machine learning algorithm for RAS/RAF/MEK/ERK pathway mutations correlates with detection of mutations as well as prediction of outcomes from samples obtained in this study. |
Up to 5 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Ardaman Shergill, Alliance for Clinical Trials in Oncology
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Neoplasmer efter histologisk typ
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gallvägssjukdomar
- Neoplasmer, körtel och epitel
- Adenocarcinom
- Carcinom
- Gallblåsan sjukdomar
- Neoplasmer i gallvägarna
- Kolangiokarcinom
- Klatskins tumör
- Neoplasmer i gallblåsan
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Undersökningstekniker
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Kirurgiska ingrepp, operativ
- Cytologiska tekniker
- Cytodiagnos
- Enzymer och koenzymer
- Koordinationskomplex
- Pyrimidiner
- Diagnostiska tekniker, kirurgiska
- Kemitekniker, analytiska
- Spektrumanalys
- Formyltetrahydrofolat
- Tetrahydrofolat
- Folinsyra
- Pteriner
- Pteridiner
- Uracil
- Pyrimidinoner
- Koenzymer
- Oxaliplatin
- Fluorouracil
- Leucovorin
- Biopsi
- Provhantering
- Magnetresonansspektroskopi
- binimetinib
- dehydroftorafur
Andra studie-ID-nummer
- NCI-2022-07833
- U10CA180821 (U.S.S. NIH-anslag/kontrakt)
- NCI-2022-07833 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- EAY191-A6 (Annan identifierare: CTEP)
- EAY191-A6 (Annan identifierare: Alliance for Clinical Trials in Oncology)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .